Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

pulmo biotech inc. - PLSE

PLSE

Close Chg Chg %
16.12 1.46 9.06%

Open Market

17.58

+1.46 (9.06%)

Volume: 103.07K

Last Updated:

Nov 22, 2024, 2:49 PM EDT

Trade Now

Company Overview: pulmo biotech inc. - PLSE

PLSE Key Data

Open

$16.27

 Day Range

16.05 - 17.60

52 Week Range

6.51 - 22.69

 Market Cap

$991.65M

Shares Outstanding

61.52M

 Public Float

17.10M

Beta

1.75

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.81

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

185.85K

  

PLSE Performance

1 Week
 
 -3.12%
 
1 Month
 
 -8.51%
 
3 Months
 
 -24.95%
 
1 Year
 
 121.73%
 
5 Years
 
 17.84%
 

PLSE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About pulmo biotech inc. - PLSE

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

PLSE At a Glance

Pulse Biosciences, Inc.
3957 Point Eden Way
Hayward, California 94545
Phone 1-510-906-4600 Revenue 0.00
Industry Medical Specialties Net Income -42,210,000.00
Sector Health Technology Employees 56
Fiscal Year-end 12 / 2024
View SEC Filings

PLSE Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 15.216
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -13.047
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.017

PLSE Efficiency

Revenue/Employee N/A
Income Per Employee -753,750.00
Receivables Turnover N/A
Total Asset Turnover N/A

PLSE Liquidity

Current Ratio 6.757
Quick Ratio 6.757
Cash Ratio 6.614

PLSE Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -59.70
Return on Equity -200.465
Return on Total Capital -78.891
Return on Invested Capital -67.893

PLSE Capital Structure

Total Debt to Total Equity 20.613
Total Debt to Total Capital 17.09
Total Debt to Total Assets 15.038
Long-Term Debt to Equity 18.228
Long-Term Debt to Total Capital 15.113
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pulmo Biotech Inc. - PLSE

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - 1.42M 700.00K
-
Sales Growth
- - -50.63% -100.00%
-
Cost of Goods Sold (COGS) incl D&A
1.09M 3.11M 13.28M 1.21M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.09M 1.15M 1.35M 1.21M
Depreciation
430.00K 480.00K 690.00K 542.00K
Amortization of Intangibles
665.00K 666.00K 665.00K 665.00K
COGS Growth
-5.60% +184.38% +326.49% -90.91%
Gross Income
(1.09M) (1.70M) (12.58M) (1.21M)
Gross Income Growth
+5.60% -54.89% -641.80% +90.41%
Gross Profit Margin
- - -119.61% -1,797.29%
-
2020 2021 2022 2023 5-year trend
SG&A Expense
48.87M 61.32M 45.48M 42.37M
Research & Development
26.44M 28.64M 20.56M 27.80M
Other SG&A
22.43M 32.68M 24.92M 14.57M
SGA Growth
+4.44% +25.47% -25.84% -6.84%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(49.97M) (63.01M) (58.06M) (43.57M)
Non Operating Income/Expense
- - 114.00K 2.46M
-
Non-Operating Interest Income
- - 114.00K 2.46M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 646.00K 448.00K 1.10M
Interest Expense Growth
- - -30.65% +145.54%
-
Gross Interest Expense
- 646.00K 448.00K 1.10M
Interest Capitalized
- - - -
-
Pretax Income
(49.85M) (63.66M) (58.51M) (42.21M)
Pretax Income Growth
-6.13% -27.70% +8.10% +27.85%
Pretax Margin
- - -4,489.42% -8,357.86%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(49.85M) (63.66M) (58.51M) (42.21M)
Minority Interest Expense
- - - -
-
Net Income
(49.85M) (63.66M) (58.51M) (42.21M)
Net Income Growth
-6.13% -27.70% +8.10% +27.85%
Net Margin Growth
- - -4,489.42% -8,357.86%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(49.85M) (63.66M) (58.51M) (42.21M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(49.85M) (63.66M) (58.51M) (42.21M)
EPS (Basic)
-2.1443 -2.2765 -1.724 -0.8787
EPS (Basic) Growth
+5.29% -6.17% +24.27% +49.03%
Basic Shares Outstanding
23.25M 27.96M 33.94M 48.04M
EPS (Diluted)
-2.1443 -2.2765 -1.724 -0.8787
EPS (Diluted) Growth
+5.29% -6.17% +24.27% +49.03%
Diluted Shares Outstanding
23.25M 27.96M 33.94M 48.04M
EBITDA
(48.87M) (61.87M) (56.70M) (42.37M)
EBITDA Growth
-4.44% -26.60% +8.35% +25.28%
EBITDA Margin
- - -4,363.05% -8,100.29%
-

Snapshot

Average Recommendation HOLD Average Target Price 5.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.156 Median PE on CY Estimate N/A
Year Ago Earnings -0.705 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Pulmo Biotech Inc. - PLSE

Date Name Shares Transaction Value
Jul 23, 2024 Burke T. Barrett President and CEO; Director 11,629 Exercise of in-the-money or at-the-money derivative security Non-derivative transaction at $11 per share 127,919.00
Jul 23, 2024 Burke T. Barrett President and CEO; Director 12,172 Exercise of in-the-money or at-the-money derivative security Non-derivative transaction at $11 per share 133,892.00
Jul 23, 2024 Burke T. Barrett President and CEO; Director N/A Exercise of in-the-money or at-the-money derivative security 0.00
Jul 23, 2024 Burke T. Barrett President and CEO; Director N/A Exercise of in-the-money or at-the-money derivative security 0.00
Jun 25, 2024 Robert William Duggan Director 20,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2024 Robert William Duggan Director 16,247 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2024 Manmeet Singh Soni Director 20,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2024 Mahkam Zanganeh Director 20,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2024 Mahkam Zanganeh Director 8,247 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2024 Richard van den Broek Director 20,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2024 Richard van den Broek Director 11,649 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Dec 13, 2023 Robert William Duggan Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 7, 2023 Robert William Duggan Director 285,544 Open market or private purchase of non-derivative security Non-derivative transaction at $10.38 per share 2,963,946.72
Dec 7, 2023 Robert William Duggan Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Pulmo Biotech Inc. in the News